Evaluation of Safety and Efficacy of Three Flavors of Supportan® Drink in Cancer Patients in Taiwan

Fresenius Kabi

Status

Not yet enrolling

Conditions

Malnutrition (Calorie)

Cancer

Treatments

Dietary Supplement: Supportan® Drink, flavour Pineapple-Coconut

Dietary Supplement: Supportan® Drink, flavour Tropical Fruits

Dietary Supplement: Supportan® Drink, flavour Cappuccino

Study type

Interventional

Funder types

Industry

Identifiers

NCT06902402

Supp-015-CEN

Details and patient eligibility

About

The goal of this clinical trial is to demonstrate safety and efficacy of Supportan® Drink (three flavors:Tropical Fruits, Cappuccino, and Pineapple-Coconut), administered as oral nutritional supplement, that will be taken in addition to the patient's normal dietary intake to meet the daily nutritional targets. in cancer patients. The main questions it aims to answer are:

Primary Efficacy Endpoint 1. Change in body weight from Baseline to end of treatment at Week 4 (Week 4 -Baseline) Secondary Efficacy Endpoints

Change in CRP from Baseline to Week 2 and to end of treatment at Week 4 (Week 2 - Baseline, Week 4 -Baseline)

Participants will be enrolled in one of three flavor group by his/her recruiting time. Each subject needs visit hospital at baseline, week 2 and week 4 for checkups and test. And he/she needs take two bottles of Supportan Drink per day. During the study periods, subjects need write down his/her dietary records every day for evaluation.

Enrollment

135 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients receiving chemotherapy and/or radiotherapy, or immunotherapy, or targeted therapy;
Patient with diagnosed cancer of any type (e.g., head and neck cancer, lung cancer, digestive tract cancer, breast cancer);
Patient with or at risk of malnutrition defined as meeting Malnutrition Universal Screening Tool (MUST) with score ≥2;
Capable of using oral nutritional supplementation;
Written informed consent from patient.

Exclusion criteria

Patient with documented diagnosis of liver, kidney or heart disease in the hospital's electronic medical record (EMR); severity of disease evaluated by Investigator as not being suitable to participate in this study;
Current alcohol or substance abuse as assessed by Investigator;
Patient had a stroke in the past year and is after Investigator assessment judged as not yet clinically stable at the time of screening;
Patients who are diagnosed with mental illness or depression assessed by the Investigator as too severe for being suitable to participate in this study;
Pregnant or breastfeeding woman;
Allergic to any ingredient of the investigational products;
Patients receiving or having received standard (not disease specific) oral nutritional supplements (ONS), standard enteral formula/tube feeding or standard parenteral cancerspecific nutrition supplements in the last 3 days;
Patients receiving or having received ONS, enteral formula/tube feeding or parenteral nutrition with high fish oil or high EPA/DHA content (above 1 g/day) in the last 28 days;
Current use of medication, food supplements or ONS containing more than 500 mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)/day or fish oil capsules/supplements containing more than 500 mg EPA and DHA/day at screening;
Transfusion of blood products within 1 week before screening;
Surgery scheduled during the trial;
Participation in other clinical trials using investigational drugs within 14 days before the start of the trial or during the trial.